Floatz logo

SEPANTRONIUM

Carcinoma, Non-Small Cell Lung

National Cancer Institute (NCI)Small moleculePhase 2Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Carcinoma, Non-Small Cell Lung cohort.

Asset / SponsorPhaseRating
Sigvotatug Vedotin
Pfizer
Phase 3BB
Opnurasib
Novartis Pharmaceuticals
Phase 3BB
Sorafenib
Bayer
Phase 3BB
Tirelizumab
Second Affiliated Hospital of Guangzhou Medical University
Phase 2BB
5-azacytidine
National Cancer Institute (NCI)
Phase 2BB

View all 14 →

Same molecule, other indications

SEPANTRONIUM is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
58 / 100
View asset →
prostate cancerDormant
B
Indicative ·
58 / 100
View asset →
melanomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →